$PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb

$pacb Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000129913020000122 Filed on August 06, 2020

Income Statement

Concept	2020 Q2	2019 Q2	2019 Q1
Revenue	$19.08M	$24.62M	$16.43M
YoY Change	-22.5%	14.1%	-15.17%
Cost Of Revenue	$10.46M	$15.01M	$11.31M
YoY Change	-30.28%	17.99%	-6.31%
Gross Profit	$6.613M	$9.613M	$5.117M
YoY Change	-31.21%	8.47%	-29.87%
Gross Profit Margin	34.66%	39.04%	31.15%
Selling, General & Admin	$15.13M	$19.08M	$19.77M
YoY Change	-20.73%	27.73%	32.36%
% of Gross Profit	228.75%	198.51%	386.28%
Research & Development	$15.01M	$14.91M	$15.49M
YoY Change	0.67%	-4.79%	-5.06%
% of Gross Profit	226.98%	155.1%	302.62%
Depreciation & Amortization	$1.590M	$1.790M	$1.796M
YoY Change	-11.17%	-1.1%	-0.33%
% of Gross Profit	24.04%	18.62%	35.1%
Operating Expenses	$30.14M	$33.99M	$35.25M
YoY Change	-11.34%	11.06%	12.82%
Operating Profit	-$23.52M	-$24.38M	-$30.13M
YoY Change	-3.51%	12.12%	25.83%
Interest Expense	$0.00	$644.0K	$625.0K
YoY Change	-100.0%	-207.33%	7.57%
% of Operating Profit
Other Income/Expense, Net	$438.0K	$428.0K	$435.0K
YoY Change	2.34%	-314.0%	23.93%
Pretax Income	-$23.09M	-$24.60M	-$30.32M
YoY Change	-6.14%	9.14%	25.39%
Income Tax
% Of Pretax Income
Net Earnings	-$23.09M	-$24.60M	-$30.32M
YoY Change	-6.14%	9.12%	25.41%
Net Earnings / Revenue	-120.98%	-99.9%	-184.62%
Basic Earnings Per Share	-$0.15		-$0.20
Diluted Earnings Per Share	-$0.15	-$161.0K	-$0.20
COMMON SHARES
Basic Shares Outstanding	154.2M	152.7M	151.3M
Diluted Shares Outstanding	154.2M		151.3M

Balance Sheet

Concept	2020 Q2	2019 Q2	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$124.4M	$80.08M	$91.75M
YoY Change	55.32%	26.11%	15.7%
Cash & Equivalents	$43.34M	$30.36M	$38.21M
Short-Term Investments	$81.03M	$49.72M	$53.54M
Other Short-Term Assets	$2.900M	$2.500M	$2.800M
YoY Change	16.0%	25.0%	33.33%
Inventory	$16.77M	$17.40M	$19.65M
Prepaid Expenses
Receivables	$11.35M	$12.12M	$7.279M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$150.9M	$98.91M	$112.6M
YoY Change	52.6%	2.6%	-2.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$27.73M	$33.46M	$33.61M
YoY Change	-17.11%	-7.32%	-8.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$41.00K	$41.00K	$65.00K
YoY Change	0.0%	-99.09%	-98.56%
Total Long-Term Assets	$62.71M	$71.67M	$72.99M
YoY Change	-12.51%	76.1%	77.16%
TOTAL ASSETS
Total Short-Term Assets	$150.9M	$98.91M	$112.6M
Total Long-Term Assets	$62.71M	$71.67M	$72.99M
Total Assets	$213.6M	$170.6M	$185.6M
YoY Change	25.25%	24.42%	18.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.436M	$8.011M	$8.740M
YoY Change	-7.18%	90.74%	1.63%
Accrued Expenses	$12.20M	$14.11M	$11.16M
YoY Change	-13.5%	29.42%	9.39%
Deferred Revenue	$6.932M	$6.707M	$6.428M
YoY Change	3.35%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$15.20M	$14.90M
YoY Change	-100.0%
Total Short-Term Liabilities	$130.9M	$49.45M	$45.10M
YoY Change	164.62%	121.76%	81.11%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Long-Term Liabilities	$41.40M	$45.40M	$45.60M
YoY Change	-8.81%	198.68%	196.1%
Total Long-Term Liabilities	$41.40M	$45.40M	$45.60M
YoY Change	-8.81%	54.95%	55.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$130.9M	$49.45M	$45.10M
Total Long-Term Liabilities	$41.40M	$45.40M	$45.60M
Total Liabilities	$172.3M	$94.83M	$90.73M
YoY Change	81.65%	83.78%	67.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.088B	-$1.037B	-$1.012B
YoY Change	4.92%		15.11%
Common Stock	$154.0K	$153.0K	$153.0K
YoY Change	0.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.39M	$75.75M	$94.85M
YoY Change
Total Liabilities & Shareholders Equity	$213.6M	$170.6M	$185.6M
YoY Change	25.25%	24.42%	18.28%

Cashflow Statement

Concept	2020 Q2	2019 Q2	2019 Q1
OPERATING ACTIVITIES
Net Income	-$23.09M	-$24.60M	-$30.32M
YoY Change	-6.14%	9.12%	25.41%
Depreciation, Depletion And Amortization	$1.590M	$1.790M	$1.796M
YoY Change	-11.17%	-1.1%	-0.33%
Cash From Operating Activities	-$23.79M	-$17.56M	-$25.31M
YoY Change	35.48%	21.1%	34.84%
INVESTING ACTIVITIES
Capital Expenditures	-$320.0K	-$620.0K	$1.253M
YoY Change	-48.39%	-54.41%	264.24%
Acquisitions
YoY Change
Other Investing Activities	-$2.540M	$8.420M	$39.24M
YoY Change	-130.17%	-37.86%	-629.55%
Cash From Investing Activities	-$2.860M	$7.820M	$37.98M
YoY Change	-136.57%	-35.85%	-590.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$6.690M
YoY Change			169.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	630.0K	1.400M	6.690M
YoY Change	-55.0%	-1655.56%	-81.14%
NET CHANGE
Cash From Operating Activities	-23.79M	-17.56M	-25.31M
Cash From Investing Activities	-2.860M	7.820M	37.98M
Cash From Financing Activities	630.0K	1.400M	6.690M
Net Change In Cash	-26.02M	-8.340M	19.36M
YoY Change	211.99%	247.5%	116.3%
FREE CASH FLOW
Cash From Operating Activities	-$23.79M	-$17.56M	-$25.31M
Capital Expenditures	-$320.0K	-$620.0K	$1.253M
Free Cash Flow	-$23.47M	-$16.94M	-$26.57M
YoY Change	38.55%	28.92%	38.97%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Entity Central Index Key EntityCentralIndexKey	0001299130
CY2020Q2	pacb	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
CY2019Q4	pacb	Contract Termination ContractTermination
CY2020Q2	pacb	Contract Termination ContractTermination
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Derivative Liabilities DerivativeLiabilities
CY2020Q2	us-gaap	Derivative Liabilities DerivativeLiabilities
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure
CY2020Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-34899
	dei	Entity Registrant Name EntityRegistrantName	Pacific Biosciences of California, Inc.
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	32675000
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	16-1590339
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1305 O’Brien Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Menlo Park
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94025
	dei	City Area Code CityAreaCode	650
	dei	Local Phone Number LocalPhoneNumber	521-8000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	PACB
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	154408829
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43342000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29627000
CY2020Q2	us-gaap	Short Term Investments ShortTermInvestments	76621000
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	19472000
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11346000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15266000
CY2020Q2	us-gaap	Inventory Net InventoryNet	16768000
CY2019Q4	us-gaap	Inventory Net InventoryNet	13312000
CY2020Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2862000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3369000
CY2020Q2	us-gaap	Assets Current AssetsCurrent	150939000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	81046000
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	27733000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30070000
CY2020Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	31435000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32827000
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3500000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4000000
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	41000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	42000
CY2020Q2	us-gaap	Assets Assets	213648000
CY2019Q4	us-gaap	Assets Assets	147985000
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	7436000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8368000
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12203000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13242000
CY2020Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6932000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7610000
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4103000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3837000
CY2019Q4	pacb	Notes Payable Net Of Discount Current NotesPayableNetOfDiscountCurrent	15871000
CY2020Q2	pacb	Deferred Gain From Reverse Termination Fee DeferredGainFromReverseTerminationFee	98000000
CY2020Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2188000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	225000
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	130862000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	49153000
CY2020Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1531000
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1951000
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39863000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41964000
CY2020Q2	us-gaap	Liabilities Liabilities	172256000
CY2019Q4	us-gaap	Liabilities Liabilities	93068000
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	154318000
CY2020Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	154318000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	153119000
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	153119000
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	154000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	153000
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1129091000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1120999000
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	243000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	5000
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1088096000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1066240000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	41392000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	54917000
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	213648000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	147985000
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17077000
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	24621000
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	41046000
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10464000
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	15008000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18574000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	26316000
CY2020Q2	us-gaap	Gross Profit GrossProfit	6613000
CY2019Q2	us-gaap	Gross Profit GrossProfit	9613000
	us-gaap	Gross Profit GrossProfit	14101000
	us-gaap	Gross Profit GrossProfit	14730000
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15010000
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14910000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30260000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	30395000
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15127000
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	19083000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	40074000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38849000
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	30137000
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	33993000
	us-gaap	Operating Expenses OperatingExpenses	70334000
	us-gaap	Operating Expenses OperatingExpenses	69244000
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23524000
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-24380000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-56233000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-54514000
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	34000000
CY2019Q2	us-gaap	Interest Expense InterestExpense	644000
	us-gaap	Interest Expense InterestExpense	267000
	us-gaap	Interest Expense InterestExpense	1269000
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	438000
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	428000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	676000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	863000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-23086000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-24596000
	us-gaap	Net Income Loss NetIncomeLoss	-21824000
	us-gaap	Net Income Loss NetIncomeLoss	-54920000
CY2020Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	213000
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	11000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	238000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	53000
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22873000
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24585000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21586000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54867000
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	154172
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	152776
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	153229
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	152029
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	60403000
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-23086000
CY2020Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	213000
CY2020Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	628000
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3234000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	41392000
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	94850000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-24596000
CY2019Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	11000
CY2019Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1400000
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4089000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	75754000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	54917000
	us-gaap	Net Income Loss NetIncomeLoss	-21824000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	238000
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	827000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7266000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	41392000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	114061000
	us-gaap	Net Income Loss NetIncomeLoss	-54920000
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	53000
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8090000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8470000
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	75754000
	us-gaap	Net Income Loss NetIncomeLoss	-21824000
	us-gaap	Net Income Loss NetIncomeLoss	-54920000
	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	34000000
	us-gaap	Depreciation Depreciation	3246000
	us-gaap	Depreciation Depreciation	3586000
	pacb	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	1392000
	pacb	Operating Lease Right Of Use Asset Amortization OperatingLeaseRightOfUseAssetAmortization	1289000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	129000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	574000
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	16000
	us-gaap	Share Based Compensation ShareBasedCompensation	7266000
	us-gaap	Share Based Compensation ShareBasedCompensation	8470000
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	177000
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	677000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1039000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	685000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3528000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3822000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	40000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-524000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-388000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3888000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1039000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3198000
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	1098000
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-734000
	us-gaap	Operating Lease Payments OperatingLeasePayments	1835000
	us-gaap	Operating Lease Payments OperatingLeasePayments	1677000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1963000
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-938000
	pacb	Increase Decrease In Deferred Gain From Reverse Termination Fee IncreaseDecreaseInDeferredGainFromReverseTerminationFee	98000000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	51574000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-42872000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	436000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1866000
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	119200000
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	36748000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	62450000
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	84410000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57186000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	45796000
	pacb	Proceeds From Contract Termination ProceedsFromContractTermination	34000000
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	16000000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	827000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8090000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18827000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8090000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	13215000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11014000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33627000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23344000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46842000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34358000
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43342000
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30358000
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3500000
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	4000000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46842000
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34358000
	pacb	Transfer Of Inventory To Property And Equipment TransferOfInventoryToPropertyAndEquipment	366000
	pacb	Transfer Of Inventory To Property And Equipment TransferOfInventoryToPropertyAndEquipment	1427000
	pacb	Merger Termination MergerTermination	<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 2 </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">TERMINATION OF MERGER WITH ILLUMINA</span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 1, 2018, we entered into an Agreement and Plan of Merger (as amended, the “Merger Agreement”) with Illumina, Inc. (“Illumina”) and FC Ops Corp., a wholly owned subsidiary of Illumina (“Merger Subsidiary”). On January 2, 2020, we, Illumina and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Merger Subsidiary,</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> entered into an agreement to terminate the Merger Agreement (the “Termination Agreement”). As part of the Termination Agreement, Illumina paid us a $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">98.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million termination fee (the “Reverse Termination Fee”), from which we paid our financial advisor associated fees of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">6.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in April 2020, which is less than the amount we initially expected. In addition, Illumina paid us cash payments (“Continuation Advances”) of $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">34.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million during the first quarter of 2020. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">However, pursuant to the Termination Agreement, in the event that, on or prior to September 30, 2020, we enter into a definitive agreement providing for, or consummate, a Change of Control Transaction (as defined in the Termination Agreement) (“Change of Control Transaction”), then we may be required to repay the Reverse Termination Fee (without interest) to Illumina in connection with the consummation of such Change of Control Transaction. If such Change of Control Transaction is not consummated by the two-year anniversary of the execution of the definitive agreement for such Change of Control Transaction, then we will not be required to repay the Reverse Termination Fee. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Please refer to “Note 5. Balance Sheet Components” for the accounting treatment of the Reverse Termination Fee.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> In addition, up to the $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">52.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million of the Continuation Advances paid to us are repayable without interest to Illumina if, within </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">two years</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of March 31, 2020, we enter into, or consummate a Change of Control Transaction or raise at least $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">100</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in equity in a single transaction or debt financing </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">(that may have multiple closings),</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> with the amount repayable dependent on the amount raised by us. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Please refer to “Note 3. Summary of Significant Accounting Policies” for the accounting treatment of the Continuation Advances.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 10pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p>
CY2020Q1	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	98000000.0
CY2020Q2	pacb	Payments For Advisor Fees PaymentsForAdvisorFees	6000000.0
CY2020Q1	pacb	Proceeds From Contract Termination ProceedsFromContractTermination	34000000.0
	pacb	Proceeds From Contract Termination ProceedsFromContractTermination	52000000.0
	pacb	Merger Agreement Period In Which Company Must Repay Continuation Advances If Change Of Control Transaction Is Entered Into With Third Party MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty	P2Y
	pacb	Merger Agreement Continuation Advances Repayable Minimum Company Must Raise In Equity Or Debt Financing In Single Transaction MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction	100000000
	us-gaap	Basis Of Accounting BasisOfAccounting	<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Basis of Presentation and Consolidation </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">In the opinion of management, our accompanying unaudited condensed consolidated financial statements (“Financial Statements”) have been prepared on a consistent basis with our December 31, 2019 audited consolidated financial statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the statements in accordance with </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">accounting principles generally accepted in the United States</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (“U.S. GAAP”). These Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019. The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results to be expected for the entire year or any future periods.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The condensed consolidated financial statements include the accounts of Pacific Biosciences and our wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated. </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Use of Estimates </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Our estimates include, but are not limited to, the valuation of inventory, the determination of stand-alone selling prices for revenue recognition, the valuation of a financing derivative and long-term notes, the probability of repaying the Continuation Advances and Reverse Termination Fee to Illumina, the valuation and recognition of share-based compensation, the expected renewal period for service contracts to derive the amortization period for capitalized commissions, the useful lives assigned to long-lived assets, the computation of provisions for income taxes and the determination of the internal borrowing rate used in calculating the operating lease right-of-use assets and operating lease liabilities. Actual results could differ materially from these estimates. </span></p>
CY2020Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	43342000
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	29627000
CY2020Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	76621000
CY2019Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	19472000
CY2020Q2	pacb	Long Term Restricted Cash Fair Value Disclosure LongTermRestrictedCashFairValueDisclosure	3500000
CY2019Q4	pacb	Long Term Restricted Cash Fair Value Disclosure LongTermRestrictedCashFairValueDisclosure	4000000
CY2020Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	123463000
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	53099000
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2019Q4	pacb	Proceeds From Contract Termination ProceedsFromContractTermination	18000000.0
CY2020Q1	pacb	Proceeds From Contract Termination ProceedsFromContractTermination	34000000.0
	pacb	Merger Agreement Period In Which Company Must Repay Continuation Advances If Change Of Control Transaction Is Entered Into With Third Party MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty	P2Y
	pacb	Merger Agreement Continuation Advances Repayable Minimum Company Must Raise In Equity Or Debt Financing In Single Transaction MergerAgreementContinuationAdvancesRepayableMinimumCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction	100000000
	pacb	Merger Agreement Period In Which Company Must Raise In Equity Or Debt Financing In Single Transaction MergerAgreementPeriodInWhichCompanyMustRaiseInEquityOrDebtFinancingInSingleTransaction	P2Y
CY2020Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0
CY2020Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0
CY2020Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	34000000.0
CY2019	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	18000000.0
	pacb	Fair Value Assets Liabilities Transfer Between Levels FairValueAssetsLiabilitiesTransferBetweenLevels	0
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Concentration and Other Risks </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.44in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">For the three and six months ended June 30, 2020, Gene Company Limited accounted for approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">15</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">11</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%, respectively, of our total revenue during the period with no other customer exceeding 10% during those periods. For the three and six months ended June 30, 2019, Gene Company Limited accounted for approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">23</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% and </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">20</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of our total revenue, respectively, with no other customer exceeding 10% during those periods. </span><span style="white-space:pre-wrap; color: #000000;font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Gene Company Limited is our primary distributor in China.</span></p>
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15266000
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15234000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1066240000
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1066272000
CY2019Q4	us-gaap	Inventory Net InventoryNet	13312000
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4500000
CY2020Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	119720000
CY2020Q2	pacb	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	243000
CY2020Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	119963000
CY2019Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	49094000
CY2019Q4	pacb	Available For Sale Securities Gross Unrealized Gain Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments	6000
CY2019Q4	pacb	Available For Sale Securities Gross Unrealized Loss Accumulated In Investments AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments	1000
CY2019Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	49099000
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	81034000
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	5635000
CY2020Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	86669000
CY2020Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5289000
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3966000
CY2020Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	5795000
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4594000
CY2020Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5684000
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4752000
CY2020Q2	us-gaap	Inventory Net InventoryNet	16768000
CY2020Q2	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-500000
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3500000
CY2020Q1	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	98000000.0
CY2020Q2	us-gaap	Accrued Professional Fees Current And Noncurrent AccruedProfessionalFeesCurrentAndNoncurrent	6000000.0
	pacb	Merger Agreement Period In Which Company Must Repay Continuation Advances If Change Of Control Transaction Is Entered Into With Third Party MergerAgreementPeriodInWhichCompanyMustRepayContinuationAdvancesIfChangeOfControlTransactionIsEnteredIntoWithThirdParty	P2Y
CY2020Q2	pacb	Deferred Gain From Reverse Termination Fee DeferredGainFromReverseTerminationFee	98000000.0
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent	16000000.0
CY2020Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	16000000.0
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4500000
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4000000.0
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4000000.0
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4000000.0
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0
CY2020Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	16000000.0
CY2020Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	0
	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">NOTE 6. COMMITMENTS AND CONTINGENCIES </span><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 13.5pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 11pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Leases</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">As of June 30, 2020, we leased approximately </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">180,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> square feet in 1305 O’Brien Drive, Menlo Park, California, where we house our headquarters, research and development, service and support functions. We also leased a sales office facility in Singapore and engineering support facilities in Allen, Texas.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On July 22, 2015, we entered into a lease agreement with respect to our facility located at 1305 O’Brien Drive, Menlo Park, California. The term of the O’Brien Lease is one hundred thirty-two (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">132</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">) months. In December 2016, we entered into an amendment to the O’Brien Lease which defined the commencement date of the lease to be October 25, 2016, notwithstanding that such substantial completion did not occur until the first quarter of 2017. Base monthly rent was abated for the first six (6) months of the lease term and thereafter was $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">540,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per month during the first year of the lease term, with specified annual increases thereafter until reaching $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">711,000</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> per month during the last twelve (12) months of the lease term. If the rent is not received within </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">five days</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> of the due date, there will be an additional sum equal to </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% of the amount overdue as a late charge. Any amount not paid within </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">10</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> days after receipt of landlord’s written notice will bear interest from the date due until paid, at the lesser rate of (1) the prime rate of interest as published in the Wall Street Journal, plus </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">% or (2) the maximum rate allowed by law, in addition to the late payment charge. We were required to establish a letter of credit for the benefits of the landlord and to submit $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.5</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million as a deposit for the letter of credit in October 2015. Subsequently pursuant to the terms of the O’Brien Lease, at May 1, 2019 the $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.5</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in restricted cash was reduced to $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and at May 1, 2020 the $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4.0</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million in restricted cash was reduced to $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.5</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">All of our leases are operating leases. Operating lease assets and liabilities are reflected within “Operating lease right-of-use assets, net”, “Operating lease liabilities, current” and “Operating lease liabilities, non-current” on the condensed consolidated balance sheets. These assets and liabilities are recognized at the commencement date based on the present value of remaining minimum lease payments over the lease term using our estimated secured incremental borrowing rates at the effective date of January 1, 2019. Lease payments included in the measurement of the lease liability comprise the base rent per the term of the Lease. Lease expense for these leases is recognized on a straight-line basis over the lease term, with variable lease payments, such as common area maintenance fees, recognized in the period those payments are incurred.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We often have options to renew lease terms for buildings. For the O’Brien Lease, the renewal option is </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">5</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years and the rent will be based on fair market value at the time of renewal and was not included in the lease term. In addition, certain lease arrangements may be terminated prior to their original expiration date at our discretion. We evaluate renewal and termination options at the lease commencement date to determine if we are reasonably certain to exercise the option on the basis of economic factors. The weighted average remaining lease term for our operating leases as of June 30, 2020 was </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.3</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> years.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The discount rate implicit within our leases is generally not determinable and therefore we determine the discount rate based on our incremental borrowing rate. The incremental borrowing rate for our leases is determined based on lease term and currency in which lease payments are made, adjusted for impacts of collateral. The weighted average discount rate used to measure our operating lease liabilities as of June 30, 2020 was </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7.9</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">%.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">The following table presents information as to the amount and timing of cash flows arising from our operating leases as of June 30, 2020:</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><div><div style="text-align:left"><table dir="ltr" style="border: none;border-collapse: collapse;margin-bottom: .001pt;margin-left: 0;margin-right: auto;width: 100%;"><tr style="height: 0.01in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><span style="white-space:pre-wrap; "/><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 1pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 1pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Maturity of Lease Liabilities</span></p></td><td colspan="2" style="background: white;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Amount </span></p></td></tr><tr style="height: 0.21in;"><td style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Years ending December 31,</span></p></td><td colspan="2" style="background: white;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 0.0%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 8pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;text-align: center;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 8pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">(in thousands)</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Remaining of 2020</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">$</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.13in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3,597</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2021</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.13in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,328</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2022</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.13in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,502</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2023</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.13in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,704</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">2024</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.13in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">7,920</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Thereafter</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.13in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">23,598</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Total undiscounted operating lease payments</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.13in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">57,649</span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Less: imputed interest</span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.09in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> (</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">13,683</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">)</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Present value of operating lease liabilities </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.13in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43,966</span></p></td></tr><tr style="height: 0.18in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top: double #000000 2.5pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Balance Sheet Classification</span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.08in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td></tr><tr style="height: 0.21in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liabilities, current</span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.13in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">4,103</span></p></td></tr><tr style="height: 0.21in;"><td style="background: #CCEEFF;border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease liabilities, non-current</span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="background: #CCEEFF;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.13in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">39,863</span></p></td></tr><tr style="height: 0.25in;"><td style="border-bottom-style: none;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 74.8%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: bold;margin: 0;padding: 0;">Total operating lease liabilities</span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: middle;width: 4.5%;"><p dir="ltr" style="text-align:left; font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0.05pt;"><span style="white-space:pre-wrap; font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p></td><td style="border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top: solid #000000 1.0pt;padding-bottom: 0;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 20.8%;"><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0.13in;margin-top: 0.05pt;text-align: right;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">43,966</span></p></td></tr></table></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 13.5pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 11pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Cash Flows</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Cash paid for amounts included in the present value of operating lease liabilities was $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.8</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.6</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million, respectively, for the three and six months ended June 30, 2020 and included in operating cash flow. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 13.5pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 11pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Operating Lease Costs</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 0;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Operating lease costs were $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.6</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.1</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million for the three and six months ended June 30, 2020, respectively. Operating lease costs were $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">1.6</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million and $</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">3.1</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> million for the three and six months ended June 30, 2019, respectively. For both 2020 and 2019 the operating lease costs primarily related to our operating leases, but also included immaterial amounts for variable leases.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 13.5pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Contingencies </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">We may become involved in legal proceedings, claims and assessments from time to time in the ordinary course of business. We accrue liabilities for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 13.5pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Legal </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 13.5pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">U.S. District Court Proceedings</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On March 15, 2017, we filed a complaint in the U.S. District Court for the District of Delaware against ONT Inc. for patent infringement (C.A. No. 17-cv-275 (“275 Action”)). The complaint is based on our U.S. Patent No. 9,546,400 (the “’400 Patent”), entitled “Nanopore sequencing using n-mers” which covers novel methods for nanopore sequencing of nucleic acid molecules using the signals from multiple monomeric units. This patent was granted on January 17, 2017. We are seeking remedies including injunctive relief, damages and costs. On August 23, 2018, we filed an amended complaint, adding ONT Ltd. as a defendant in the 275 Action. On August 15, 2019, the judge granted our motion to amend the complaint in the 275 Action to add allegations of willful infringement by ONT Inc. and ONT Ltd.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On September 25, 2017, we filed a second complaint in the U.S. District Court for the District of Delaware against ONT Inc. for patent infringement (C.A. No. 17-cv-1353 (“1353 Action”)). The complaint is based on our U.S. Patent No. 9,678,056 (the “’056 Patent”) entitled “Control of Enzyme Translation in Nanopore Sequencing”, granted June 13, 2017, and U.S. Patent No. 9,738,929 (the “’929 Patent”) entitled “Nucleic Acid Sequence Analysis”, granted August 22, 2017. We are seeking remedies including injunctive relief, damages and costs. On March 28, 2018, we added a claim for infringement of our U.S. Patent No. 9,772,323 (the “’323 Patent”), entitled “Nanopore sequencing using n-mers.” On August 23, 2018 we filed an amended complaint, adding ONT Ltd. as a defendant in the 1353 Action. On August 15, 2019, the judge granted our motion to amend the complaint in the 1353 Action to add allegations of willful infringement by ONT Inc. and ONT Ltd.</span></p></div><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 0;"><span style="white-space:pre-wrap; font-size: 11pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">A trial for the U.S. District Court matters was held from March 9 through March 18, 2020. The jury determined that ONT Inc. and ONT Ltd. infringed the ‘056 Patent, the ‘400 Patent, and the ‘323 Patent, but the jury declined to find these patents valid based on enablement and, in the case of claim one of the ’056 Patent, written description and indefiniteness. The jury declined to find valid or infringed U.S. Patent No. 9,738,929. We plan to appeal the decision to the U.S. Court of Appeals for the Federal Circuit. </span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Unrelated to the preceding matters, on September 26, 2019, Personal Genomics of Taiwan, Inc. (“PGI”) filed a complaint in the U.S. District Court for the District of Delaware against us for patent infringement (C.A. No. 19-cv-1810). The complaint is based on PGI’s U.S. Patent No. 7,767,441 (the “441 Patent”). We plan to vigorously defend in this matter. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On November 20, 2019, we filed our answer to the complaint, denying infringement and seeking a declaratory judgement of invalidity of the ‘441 Patent. A trial for this matter is scheduled to begin on March 14, 2022.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On June 22, 2020, we filed a petition requesting institution of an inter-partes review (IPR) to the Patent Trial and Appeals Board (the “Board”) at the United States Patent Office requesting the Board to find a set of claims in the ‘441 invalid. On June 27, 2020, we filed a second petition requesting institution of an IPR requesting the Board to find another set of claims in the ‘441 invalid. The two petitions requesting IPRs assert that all of the claims relevant to the PGI complaint are invalid.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">On May 19, 2020, PGI filed a complaint in the Wuhan People’s Court alleging infringement of one or more claims of China patent No. CN101743321B, which is related to the ‘441 Patent. We have not received service. We plan to vigorously defend in this matter.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 13.5pt;text-align: justify;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: italic;font-weight: normal;margin: 0;padding: 0;">Other Proceedings</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 10pt;line-height: 108%;margin-bottom: 0;margin-left: 0;margin-right: 0;margin-top: 4.5pt;text-indent: 0.34in;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">From time to time, we may also be involved in a variety of other claims, lawsuits, investigations and proceedings relating to securities laws, product liability, patent infringement, contract disputes, employment and other matters that arise in the normal course of our business. In addition, third parties may, from time to time, assert claims against us in the form of letters and other communications. We record a provision for contingent losses when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. We currently do not believe that the ultimate outcome of any of the matters described above is probable or reasonably estimable, or that these matters will have a material adverse effect on our business; however, the results of litigation and claims are inherently unpredictable. Regardless of the outcome, litigation can have an adverse impact on us because of litigation and settlement costs, diversion of management resources and other factors.</span></p><p dir="ltr" style="font-family: 'Times New Roman', 'serif';font-size: 11pt;line-height: 108%;margin-bottom: .001pt;margin-left: 0;margin-right: 0;margin-top: 13.5pt;"><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 11pt;font-style: italic;font-weight: bold;margin: 0;padding: 0;">Indemnification</span></p><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">Pursuant to Delaware law and agreements entered into with each of our directors and officers, we may have obligations, under certain circumstances, to hold harmless and indemnify each of our directors and officers against losses suffered or incurred by the indemnified party in connection with their service to us, and judgements, fines, settlements and expenses related to claims arising against such directors and officers to the fullest extent permitted under Delaware law, our bylaws and certificate of incorporation. We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between such third parties and us in connection with such fundraising efforts. To the extent that any such indemnification obligations apply to the lawsuits described above, any associated expenses incurred are included within the related accrued litigation expense amounts. </span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;">No</span><span style="white-space:pre-wrap; font-family: 'Times New Roman', 'serif';font-size: 10pt;font-style: normal;font-weight: normal;margin: 0;padding: 0;"> additional liability associated with such indemnification obligations has been recorded at June 30, 2020.</span>
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4500000
CY2019Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4500000
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4000000.0
CY2019Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4000000.0
CY2020Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	3500000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	3597000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	7328000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	7502000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	7704000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	7920000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	23598000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	57649000
CY2020Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13683000
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	43966000
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4103000
CY2020Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	39863000
CY2020Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	43966000
CY2020Q2	us-gaap	Payments For Rent PaymentsForRent	1800000
	us-gaap	Payments For Rent PaymentsForRent	3600000
CY2020Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1600000
	us-gaap	Operating Lease Cost OperatingLeaseCost	3100000
CY2019Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1600000
	us-gaap	Operating Lease Cost OperatingLeaseCost	3100000
CY2020Q2	pacb	Additional Liability Associated With Indemnification Obligations AdditionalLiabilityAssociatedWithIndemnificationObligations	0
CY2020Q2	pacb	Share Based Compensation Arrangements By Share Based Payment Awards Number Of Active Plans ShareBasedCompensationArrangementsByShareBasedPaymentAwardsNumberOfActivePlans	3
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3234000
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4089000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7266000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8470000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y1M6D
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17077000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24621000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32675000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41046000
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17077000
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24621000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32675000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41046000

Files In Submission

Name	View Source	Status
0001299130-20-000122-index-headers.html	Edgar Link	pending
0001299130-20-000122-index.html	Edgar Link	pending
0001299130-20-000122.txt	Edgar Link	pending
0001299130-20-000122-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pacb-20200630.xsd	Edgar Link	pending
pacb-20200630x10q.htm	Edgar Link	pending
pacb-20200630x10q_htm.xml	Edgar Link	completed
pacb-20200630xex31_1.htm	Edgar Link	pending
pacb-20200630xex31_2.htm	Edgar Link	pending
pacb-20200630xex32_1.htm	Edgar Link	pending
pacb-20200630xex32_2.htm	Edgar Link	pending
pacb-20200630_cal.xml	Edgar Link	unprocessable
pacb-20200630_def.xml	Edgar Link	unprocessable
pacb-20200630_lab.xml	Edgar Link	unprocessable
pacb-20200630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb

2020 Q2 Form 10-Q Financial Statement

#000129913020000122 Filed on August 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PACB PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb

2020 Q2 Form 10-Q Financial Statement

#000129913020000122 Filed on August 06, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Stock $pacb